![]() G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. | ![]() Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. | ![]() Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. | ![]() Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. | ![]() Juno Therapeutics Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer. | ||
Founding Date | Founding Date 2009 | Founding Date 2008 | Founding Date 2016 | Founding Date 1980 | Founding Date 1996 | Founding Date 2013 |
Type | Type Subsidiary | Type Public | Type Private | Type Public | Type Public | Type Subsidiary |
Tags | ||||||
Locations | Locations Santa Monica, US HQ Hoofddorp, NL London, GB El Segundo, US Emeryville, US Frederick, US Oceanside, US see more | Locations Durham, US HQ | Locations London, GB HQ Stevenage, GB | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Seattle, US HQ Göttingen, DE Göttingen, DE München, DE München, DE Bothell, US Brisbane, US |
Employees | Employees 3,9671% decrease | Employees 17015% increase | Employees 695% decrease | Employees 25,200 | Employees 75,883 | Employees 1091% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 377.2 m | Valuation ($) N/A | Valuation ($) 170.4 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $111.9m (FY, 2017) |
Cost of goods | Cost of goods N/A | Cost of goods $7.2m (FY, 2023) | Cost of goods N/A | Cost of goods $12b (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $75.3m (FY, 2023) | Gross profit N/A | Gross profit $24.7b (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($48m) (FY, 2023) | Net income ($69.7m) (FY, 2023) | Net income $7.7b (FY, 2025) | Net income $14b (FY, 2025) | Net income ($437.1m) (FY, 2017) |
Operating ⚠ | ||||||
Patents (US) | Patents (US) N/A | Patents (US) 40 (FY, 2020) | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) 72 (FY, 2016) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products N/A |
Trademarks (US) | Trademarks (US) 19 (Jan, 2024) | Trademarks (US) N/A | Trademarks (US) 3 (May, 2021) | Trademarks (US) N/A | Trademarks (US) N/A | Trademarks (US) N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 85.3m | Total funding raised $ 289.6m | Total funding raised $ 138.1m | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 310m |

G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View company
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View company
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
View company
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View company